Insights

Clinical research stands at a crossroads. Behind every protocol, every trial, and every new technology is a team of professionals facing mounting pressures: shifting regulations, the rapid arrival of artificial intelligence tools, and a workforce that is both more essential and more at risk of burnout than ever before. The heart of the problem isn’t just compliance or efficiency. It’s leadership. What does it mean to truly lead in an environment where yesterday’s best practices are outpaced by tomorrow’s disruptions?

Mental health literacy comprises the knowledge, attitudes, and capabilities that enable recognition, understanding, and appropriate responses to psychological strain, even when it does not meet the criteria for diagnosable mental disorders. In leadership coaching—particularly in high-pressure environments such as clinical development—this competence shapes how coaches interpret behavior, structure conversations, and calibrate expectations.

This article reviews frequently confused clinical trial terms and explains their operational and regulatory implications, with reference to the International Council for Harmonization guideline for Good Clinical Practice and U.S. Food and Drug Administration guidance. Clear and consistent interpretation of these terms is essential for maintaining inspection readiness and ensuring high-quality study execution.

As a follow-up to Clinical Trials Day 2026, held on May 20 with the theme of “Research Rising,” a collection of industry thought leaders shared their perspectives with ACRP on what the sentiment means to them and on how they keep rising in clinical research for the sake of patients and the industry.